EP
GLMD icon

Eversept Partners’s Galmed Pharmaceuticals GLMD Stock Holding History

Eversept Partners’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-56
Closed -$119K – 69
2018
Q2 		$119K Buy
+56
New +$81.1K 0.05% 71

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Eversept Partners's GLMD Position: Q3 2018 in Review

Eversept Partners sold out of Galmed Pharmaceuticals (GLMD) in Q3 2018, closing a stake of 56 shares — an estimated $119K sold.

Eversept Partners first reported a position in GLMD in Q2 2018 and held it in 1 quarter. The position peaked at $119K in Q2 2018. 38 funds tracked by Wall St. Rank hold GLMD as of Q3 2018.

  • Eversept Partners reported no remaining Galmed Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Eversept Partners sold 56 Galmed Pharmaceuticals shares in Q3 2018, an estimated $119K.
  • Eversept Partners first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Eversept Partners's Galmed Pharmaceuticals position peaked at $119K in Q2 2018.
  • 38 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2018.

Based on Eversept Partners's 13F filing for Q3 2018, filed 14 Nov 2018.